• Text Size
  • Contrast
  • 2009/12/10
  • 3 min
  • 0

Paris, 10 December 2009

Medisse, a Dutch biomaterials company, is active in resorbable implants for soft tissue applications, based on a patented flexible polymer platform. The financing will allow Medisse to speed up the development and global commercialization of its FlexiSurge Mesh and FlexiSurge Barrier, an anti adhesion barrier.


Sandra de Vos, CEO of Medisse commented: “We are very pleased to have two investors on board that give us the opportunity to bring the company to the next level. The growing use of resorbable materials for soft tissue applications has created exciting opportunities for Medisse. We expect to complete the development of our first products, FlexiSurge Mesh and FlexiSurge Barrier, and bring these products to the market. FlexiSurge products are highly flexible and they resorb via surface erosion, resulting in unique material properties that are very useful in many soft tissue medical devices. Proceeds will also be used for developing other devices using the FlexiSurge material”.


“We are pleased to invest in another biomaterial company with products that are close to market” says Wil Hazenberg, Partner at BioGeneration Ventures. "The investment will yield significant advances in the development of the company in the coming 12 months“.


“We consider this investment as an interesting opportunity in an early stage company that has developed original approaches in polymer development” says Emmanuelle Coutanceau, Associate at Crédit Agricole Private Equity. “We are pleased to support the company in its next step of development”.


The investment was led by BioGeneration Ventures and Wil Hazenberg will join the company's board of directors. Crédit Agricole Private Equity will be represented by Emmanuelle Coutanceau.

Follow info